

- in hypothermia, 478e-2
hypoxia in, 248
in inflammatory states, 628, 628t, 629–630, 630f
lactic acidosis in, 318
in liver disease, 631
macrocytic, 81e-8f
in malabsorption syndromes, 1945
from maturation disorders, 398–399
in multiple myeloma, 714
myelophthisic, 671–672
normocytic, in rheumatoid arthritis, 2138
physical examination in, 393
in protein starvation, 630–631
refractory, 669t. *See also* Myelodysplasia
sideroblastic, 399, 451e-4t, 628t
in SLE, 2131
in thalassemia, 637
treatment of, 399
- Anesthesia (sensory abnormality), 158
Anesthetics, 54, 64, 64t
Aneuploidy, 83e-1, 83e-4
Aneurysm
 aortic. *See* Aortic aneurysm
 aortic sinus of Valsalva, 1523
 coronary artery, 271e-4f, 2192–2193
 fusiform, 1637
 intracranial, 1784–1785. *See also*
 Subarachnoid hemorrhage
 left ventricular, 1610
 mycotic. *See* Mycotic aneurysm
 popliteal artery, 1647
 renal artery, 1630f
 saccular. *See* Saccular aneurysm
 true, 1637
- Ang1/Ang2. *See* Angiopoietins
Angelman's syndrome, 83e-7, 439, 444e-2
Angiitis
 allergic. *See* Eosinophilic granulomatosis with
 polyangiitis (Churg-Strauss syndrome)
 cutaneous leukocytoclastic, 2119, 2191
 isolated granulomatous, chronic meningitis
 in, 909t
- Angina
 microvascular, 1579
 Prinzmetal's variant, 1456, 1579, 1588, **1598**
 stable, **1580**. *See also* Ischemic heart disease
 in aortic stenosis, 1530
 atherosclerosis and, 291e-4
 atypical, 1581
 exertional, 1581
 history in, 1580
 myocardial infarction probability with, 99f
 in myocardial ischemia, 95–97, 96t, 99–100,
 99f, 1439, 1581, 1594
 in orthostatic hypotension, 146
 physical examination in, 1581–1582
 severity classification of, 1581, 1581t
 threshold for development of, 1581
 treatment of, 296e-3, 1586–1587. *See also*
 Ischemic heart disease, treatment of
 unstable, 96, 96t, 97, 1593. *See also*
 Non-ST-segment elevation acute
 coronary syndrome (NSTEMI-ACS)
- Angina decubitus, 1581
Anginal equivalents, 1581
Angina pectoris, 95. *See also* Angina, stable;
 Angina, unstable
Angiocentric immunoproliferative lesion/
 angiocentric lymphoma. *See*
 Extranodal NK/T-cell lymphoma,
 nasal type
Angiodermatitis, acral, 367
Angioedema, **2117**
 classification of, 2117, 2118t
 clinical features of, 363, 2119
 definition of, 2117
 diagnosis of, 2119
 drug-induced, 381, 384t, 1623
 etiology of, 363t, 2117–2118, 2118t
 hereditary, 372e-25t, 2118, 2119, 2120
 pathophysiology of, 2119
 predisposing factors for, 2117–2118, 2118t
 treatment of, 381, 2119–2120
 vibratory, 2118
Angiofibroma, 364, 364t
Angiofibromas, 101e-6t, 2336t, 2340
Angiogenesis, 265e-4
 in gastric mucosa, 1912
 inhibition of, **102e-15**
 gene therapy for, 91e-4
 mechanisms of, 102e-16f
 therapeutic strategies, 102e-17f
 tumor, 102e-1t, 102e-13
 inhibition of, 102e-15, 102e-16f, 102e-17
 signaling pathways in, 102e-14–15,
 102e-15f, 102e-16f
 vessel formation mechanisms in,
 102e-13–15
Angiogenic switch, 102e-13
Angiography
 cerebral
 in CNS vasculitis, 441e-19f
 in CNS vasculopathy, 2568f
 complications of, 440e-10
 indications for, 440e-10
 in stroke, 2581, 2581f
 coronary. *See* Coronary angiography
 CT. *See* Computed tomography (CT)
 angiography (CTA)
 magnetic resonance. *See* Magnetic resonance
 angiography (MRA)
 pulmonary, 1634, 1666–1667
 renal intraarterial, 1628t
 spinal, 440e-10–11
Angioimmunoblastic T-cell lymphoma, 135e-4
 to 135e-5, 708
Angiokeratoma, 364t, 365, 432e-1, 436e-7f
Angioma
 cavernous, 2586
 cherry, 341t
 senile, 342f
 small intestinal, 536
 spider, 286, 1992, 2058, 2059f
Angiomyolipoma, renal, 101e-6t, 1854
Angiopoietins, 89e-3, 102e-14–15, 102e-15f,
 102e-17f
Angiosarcoma, 119e-2, 364t, 367
Angiostrongylus spp. infections
 abdominal, 1417
 clinical features of, 908t, 1412
 diagnosis of, 245e-3t, 245e-6t, 765t, 1412
 epidemiology of, 245e-3t
 life cycle of parasite, 245e-3t, 1412, 1412f
 pathogenesis of, 1412
 treatment of, 1411t, 1412
Angiotensin-converting enzyme (ACE)
 in glomerular filtration rate regulation,
 332e-2, 332e-2f
 reference values for, 2757t
 in sarcoidosis, 2209
 in sodium absorption, 332e-11
Angiotensin-converting enzyme (ACE)
 inhibitors
 action of, 1623
 adverse effects of
 acid-base disorders, 321t
 anaphylaxis, 44
 angioedema, 1623, 2118, 2119
 cough, 244, 1623
 cross-sensitivity and, 385
 cutaneous, 353, 378, 379, 381
 erectile dysfunction, 326
 hyperkalemia, 64e-2, 310
 lupus syndrome, 2218t
 renal, 291, 1623, 1800, 1801f, 1815
 transfusion-related hypotension, 138e-5–6
 for aortic aneurysm in Marfan's syndrome,
 1639
 for aortic dissection, 1641
 for diabetic nephropathy, 2426
 for heart failure, 1511, 1511f, 1512t
 for hypertension, 1623, 1624t
 in chronic kidney disease, 1817, 1821
 comparison to other agents, 1625
 in metabolic syndrome, 291e-7, 2454
 for hypokalemia, 308
 for ischemic heart disease, 1590
 metabolism of, 35
 for myocardial infarction, 1596, 1598, 1607
 for peripheral artery disease, 1645
 preoperative discontinuation of, 54
 for pulmonary edema, 1761f, 1763
 for radiation-induced cardiovascular disease,
 621
 for renal artery stenosis, 1618
 for scleroderma renal crisis, 1865, 2164
Angiotensin II
 aldosterone levels and, 306
 in blood pressure regulation, 1613–1614
 in glomerular filtration rate regulation,
 332e-2, 332e-2f, 1800
 in shock, 1745
 in sodium reabsorption, 296, 332e-11
 in urinary tract obstruction, 1872
Angiotensinogen, 1613
Angiotensin receptor blockers (ARBs)
 adverse effects of, 1623
 cutaneous, 381
 hyperkalemia, 64e-2, 310
 renal, 1800, 1801f, 1815
 aldosterone-renin ratio effects of, 2320t
 for diabetic nephropathy, 2426
 for heart failure, 1507, 1511–1512, 1512t
 for hypertension, 1623, 1624t
 in chronic kidney disease, 1817, 1821
 comparison to other agents, 1625
 in metabolic syndrome, 291e-7, 2454
 for Marfan syndrome, 445
 metabolism of, 40
 for myocardial infarction, 1607
 preoperative discontinuation of, 54
 for Raynaud's phenomenon, 2164
 for renal artery stenosis, 1618
Angle of Louis, 1443
Anidulafungin, 233, 1331, 1344t, 1352t
Aniline dyes, 575
Animal bite-wounds. *See* Bite-wounds
"Animal Rule," 261e-10
Anion gap, 317, 2757t
Anisakis/anisakiasis, 765t, 1416–1417
Anisimus, 274
Anisocoria, 196–197
Anisocytosis, 81e-1, 394, 413
Anistreplase, 758
ANK gene mutations, 653t
ANKH gene mutations, 2235
Ankle, pulse measurement in, 1446f
Ankle-brachial index (ABI), 1616, 1643
Ankylosing spondylitis, **2169**
 in adolescence, 2170
 classification of, 2169, 2169t
 clinical features of, **2170**
 aortitis, 290e-3, 1642
 murmur, 51e-6, 1443
 neck pain, 122
 ocular, 2171
 pseudoarthrosis, 2171
 sacroiliitis, 2171, 2172f
 skeletal, 1443
 spinal inflammation, 2170–2171, 2172f
 complications of, 2171
 diagnosis of, 2169t, 2171–2172, 2172f
 epidemiology of, 2169
 HLA gene association with, 373e-7, 373e-8t
 IBD and, 1958–1959, 2178–2179
 KIRs with, 372e-15t
 pathogenesis of, 2170
 pathology of, 2169–2170
 prognosis of, 2171
 treatment of, 2172–2173
 vs. vertebral osteomyelitis, 840
Annelid worm stings, 2739, 2739f
Annexin-2, 402
Annular pancreas, 2102
Annular skin lesion, 340t
Annuloaortic ectasia, 51e-6
Anogenital warts. *See* Condyloma acuminata
 (anogenital warts)